Puerto, Reynalyn B.
HRN: 19-29-61 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/02/2023
CLINDAMYCIN 300MG (CAP)
06/02/2023
06/09/2023
PO
300mg
Q6h
Infected Epidermal Inclusion Cyst
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes